Skip to main content
OPRX logo

OPRX · OptimizeRx Corp

Track OPRX — free
$6.70 -0.31 (-4.42%) At close · Nov 20
Market Cap
$126.68M
Shares
18.91M
Volume · Nov 20 186.73K Avg daily vol (3M) 190K

Price & Indicators

 

Key stats

Close
$6.70
Fri 20 Nov
Open
$6.92
Fri 20 Nov
Average volume, 30 days
218K
shares a session
Short interest
1.2M
6.3% of shares · 9.8 days to cover
Day range
$6.57$7.10
Open $6.92 Close $6.70
52-week closing range
$4.54$15.39
Close $6.70 56.5% under the high
Short volume, last session
54%
Last earnings
Nov 11, 2026
Latest filing
10-Q · Nov 13
Price history
Jan 2020 to Nov 2026

Up next

Mar 4, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue fell 20%; nine-month loss reached $(3)

OptimizeRx reported a 20% revenue decline and a $(3) net loss for the nine months ended September 30, 2026, versus $112 net income in 2025. Disclosure controls also remained ineffective due to a material weakness.

Revenue $21.62M ▼ 17.1% Net income $1.2M ▲ 53.4% Diluted EPS $0.06 ▲ 50.0%
Read from the MD&A section
3 source passages
We had a net income of $1,195 for the three months ended September 30, 2026, as compared to net income of $779 during the three months ended September 30, 2025 and a net loss of $(3) for the nine months ended September 30, 2026 as compared to a net income of $112 for the nine months ended September 30, 2025. Our net revenue decreased 17% to $21,615 for the three months ended September 30, 2026 from $26,067 for the same period in 2025, and decreased 20% to $61,963 for the nine months ended September 30, 2026 from $77,190 for the same period in 2025. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures, as defined in Rule 13a-15(e), were not effective at the reasonable assurance level due to a previously identified material weakness in our internal control over financial reporting related to controls ensuring that data received from one third-party service organization were complete and accurate. Open the document at this passage
Nov 13
Current report 8-K Events of Nov 11
Revenue guidance updated as adjusted EBITDA rises

OptimizeRx reported Q3 2026 revenue of $21.6 million, down 17%, and adjusted EBITDA of $6.3 million; it updated 2026 revenue guidance to $87-$93 million while keeping adjusted EBITDA guidance at $21-$25 million.

Financial results Read from the first part of this long document
4 source passages
OptimizeRx Reports Third Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance Revenue decreased 17% to $21.6 million in Q3 2026, compared to $26.1 million in Q3 2025. Adjusted EBITDA of $6.3 million in Q3 2026 compared to $5.1 million in Q3 2025. The Company is updating its fiscal year 2026 guidance, and now expects revenue of $87 million to $93 million and adjusted EBITDA of $21 million to $25 million. Open the document at this passage
Nov 11
Earnings call
Revenue guidance updated as adjusted EBITDA exceeds consensus

OptimizeRx reported third quarter revenue of $21.6 million and adjusted EBITDA of $6.3 million, both exceeding consensus expectations, and updated full-year 2026 revenue guidance to $87 million to $93 million while maintaining adjusted EBITDA guidance of $21 to $25 million.

3 source passages
Thank you for joining OptimizeRx third quarter fiscal 2026 earnings conference call. We're pleased to report third quarter revenue of $21.6 million and adjusted EBITDA of $6.3 million, both of which exceeded consensus expectations. we are updating the full-year 26 revenue guidance to a range of $87 million to $93 million, while maintaining our adjusted EBITDA guidance of $21 to $25 million. Open the document at this passage
Aug 13
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $20.5M ▼ 29.8% Net loss $703K Diluted EPS -$0.04
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$94.20M
Trailing 12 months
Net income (TTM)
$5.02M
Trailing 12 months
Revenue growth YoY
-17.1%
Year over year
Operating margin
12.2%
Trailing 12 months
P / E (TTM)
25.8
Trailing earnings · reciprocal yield 3.9%
FCF yield
15.7%
TTM · current market cap
Return on invested capital
5.6%
Trailing 12 months
Net cash
$9.60M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-1.2%
Year over year · fewer shares
Price change (1Y)
-50.7%
Trailing year
Short interest
6.3%
Latest settlement · 9.8 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 11, 2026
Q3 FY26

TL;DR. OptimizeRx delivered a consensus revenue and adjusted EBITDA beat, expanded profitability by more than 900 basis points, and saw encouraging 2027 RFP momentum, a returning major customer, new programmatic distribution, and lower debt. However, revenue declined 17%, 2026 contracted revenue remained approximately 20% below the prior year, full-year revenue guidance was reduced to $87 million-$93 million, and fourth-quarter execution risk increased.

Bullish
  • + Q3 revenue of $21.6 million and adjusted EBITDA of $6.3 million both exceeded consensus expectations.
  • + Adjusted EBITDA increased approximately 23%, while adjusted EBITDA margin expanded more than 900 basis points. new
  • + Contracted revenue for the 2027 RFP season was running close to 20% ahead year over year. new
  • + A previously displaced top-five client returned and began reinvesting in new solutions with OptimizeRx. new
  • + The PulsePoint integration is expected to contribute approximately 250,000 incremental NPIs to PulsePoint's network. new
  • + Debt principal repayments since June 30, 2026 reduced outstanding principal to $10.4 million. new
Bearish
  • − Q3 revenue decreased 17% to $21.6 million from $26.1 million in Q3 2025. new
  • − Full-year 2026 revenue guidance was updated to $87 million-$93 million. new
  • − Contracted revenue for 2026 continued to track approximately 20% below the comparable prior-year level. new
  • − Net revenue retention fell to 83% from 121% in the prior-year period.
  • − Management cited reduced large-customer spending, budget pressure, and spending delays associated with MFN pricing uncertainty. new
  • − Limited visibility into fourth-quarter buy-up activity increased execution risk and reduced the odds of a near-term revenue upside surprise. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Neutral Sentiment Bearish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −5%
below
Price vs 50-day avg −20%
below
RSI (14) 34
neutral
MACD trend Negative
52-week position 20%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return −27%
trailing
6-month return +27%
trailing
YTD return −45%
this year
Relative strength +36%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $8 › 200d $7 — 50d above 200d
Institutional flow Distributing
-8% holders QoQ · +13 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.28% of shares out · ▲ +10.1% MoM · 9.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
103 holders — mid 3-yr range
Squeeze score 65
elevated · 0–100
Fundamentals
Excellent
Revenue growth +19%
Y/Y
Gross margin 67%
expanding
EPS growth +125%
Y/Y
Free cash flow $18.7M
Valuation P/E 25.8
below peers
Buyback $10.0M
authorized
Balance sheet $2.3M
net debt
Quant / Vol
risk profile
Very High
Volatility 71%
annualized · 1-yr
Max drawdown −71%
past year
ATR 10.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 3 of last 5
Latest guidance · from the 8-K filed Nov 13, 2026
Revenue · fiscal year 2026 Maintained $87M – $93M
Nov 11, 2026 $87M – $93M changed to Nov 13, 2026 $87M – $93M
prior FY $109.43M midpoint −17.8% Y/Y
Adjusted EBITDA · fiscal year 2026 Non-GAAP Maintained $21M – $25M
Nov 11, 2026 $21M – $25M changed to Nov 13, 2026 $21M – $25M
Previous outlook earlier release · from the Earnings Call filed Nov 11, 2026

Still-open targets the latest release did not restate under the same label.

Contract revenue · 2027 20%
Guided vs delivered · last 5 settled
Revenue the year
guided $105M – $109M
$109.43M Beat +2.3%
Revenue full year 2024
guided at least $100M
$92.13M Miss −7.9%
Revenue for the year
guided $68M – $70M
$71.52M Beat +3.7%
Revenue fiscal first quarter ending March 31, 2023
guided $11.5M – $13M
$13M Beat +6.1%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−5% Bearish
Price vs 50-day avg
−20% Bearish
RSI (14)
34 Neutral
MACD trend
Negative Bearish
52-week position
20% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $8 › 200d $7 — 50d above 200d
Institutional flow Distributing
-8% holders QoQ · +13 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.28% of shares out · ▲ +10.1% MoM · 9.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
103 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5 Now $7 · 20% Range high $15
vs 200-day avg -5% vs 50-day avg -20%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA margin non-GAAP 29% third quarter of 2026 —
Average revenue per top 20 pharmaceutical manufacturer 2.5M Rolling Twelve Months Ended September 30, 2026 —
contracted revenue 90% full year 2026 —
EBITDA margin 29% this quarter —
EHR and e-prescribing systems 400 September —
Net revenue retention 83% Rolling Twelve Months Ended September 30, 2026 —
Percent of total revenue attributable to top 20 pharmaceutical manufacturers 53% Rolling Twelve Months Ended September 30, 2026 —
Revenue per average full-time employee 706K Rolling Twelve Months Ended September 30, 2026 —
verified healthcare professionals 800,000 September —
Average revenue per top 20 pharmaceutical manufacturers 2.66M Rolling Twelve Months Ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Health Information Services — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
OPRX
OptimizeRx Corp
this stock
$126.68M -45.4% +18.8% 25.8 6.3%
VEEV
Veeva Systems Inc
$43.10B +19.3% +28.1% 43.6 2.4%
PMDIY
Pro Medicus Ltd.
$14.81B -14.6% — — 0.0%
BTSG
BrightSpring Health Services, Inc.
$12.50B +67.8% +28.2% 34.2 5.8%
TEM
Tempus AI, Inc.
$9.86B -8.5% +83.4% — 13.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
103
% held
64.7%
Net QoQ
+1.0M sh
Top holder
Whetstone Capital Advisor…
Held Float
View
Held by Funds
Fund positions
54
View
Short & Settlement
Short Interest Rising
Shares short
1.2M
Days to cover
9.8d
Change
+108.9K sh
View
Short Volume
Short vol %
54%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
195
Value
$1.7K
As of
Oct 20, 2026
View
Off-Exchange
Off-exchange %
39.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$109.4M
Net income (FY)
$5.1M
EPS diluted
$0.27
View
Buybacks
Authorized
$10.0M
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 13, 2026
This year
16

OptimizeRx reported a 20% revenue decline and a $(3) net loss for the nine months ended September 30, 2026, versus $112 net income in 2025. Disclosure controls also remained ineffective due to a material weakness.

View
Proposed Sales
Value
$198.0K
Shares
11.1K
Filed
Aug 29, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 11, 2026
View
Investor Relations
Latest news
OptimizeRx to Participate in the…
Published
Nov 16, 2026
View

Performance

5D 20D 120D MTD YTD
OPRX -8.7% -26.8% +26.9% -28.1% -45.4%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -0.2% -17.6% +36.1% -19.4% -46.5%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$10.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1448431 CUSIP 68401U204 13F (30d) 110 filings 94 filers Visit website Investor relations